This Level II RCT tested whether adding a 6-day oral methylprednisolone taper to intraoperative dexamethasone improves pain control after total shoulder arthroplasty. 67 opioid-naive patients received a standardized multimodal regimen, then were randomized to taper or control. The study measured pain, opioid consumption, and complications over the first postoperative week and out to 1 year.
Nerve blocks and liposomal bupivacaine only cover the first 24-72 hours after shoulder surgery, leaving a pain gap right when patients reach for oxycodone. This trial shows a cheap 6-day oral steroid taper fills that gap: opioid use fell by roughly two-thirds and second refills dropped from 38% to 6%.
The mental model to carry: corticosteroids work peripherally on the inflammatory cascade, while opioids work centrally. Because the steroid acts on a different pathway with low dependence risk, it complements rather than duplicates your block.
The honest caveat is that better pain scores did not produce better ASES or shoulder function at 12 weeks, so this is an analgesia and opioid-stewardship tool, not an outcomes booster. Safety held at 1 year with no excess infection, though the trial was powered only for pain, so rare steroid or subscapularis-healing risks cannot be excluded.
This Level II RCT tested whether adding a 6-day oral methylprednisolone taper to intraoperative dexamethasone improves pain control after total shoulder arthroplasty. 67 opioid-naive patients received a standardized multimodal regimen, then were randomized to taper or control. The study measured pain, opioid consumption, and complications over the first postoperative week and out to 1 year.
Nerve blocks and liposomal bupivacaine only cover the first 24-72 hours after shoulder surgery, leaving a pain gap right when patients reach for oxycodone. This trial shows a cheap 6-day oral steroid taper fills that gap: opioid use fell by roughly two-thirds and second refills dropped from 38% to 6%.
The mental model to carry: corticosteroids work peripherally on the inflammatory cascade, while opioids work centrally. Because the steroid acts on a different pathway with low dependence risk, it complements rather than duplicates your block.
The honest caveat is that better pain scores did not produce better ASES or shoulder function at 12 weeks, so this is an analgesia and opioid-stewardship tool, not an outcomes booster. Safety held at 1 year with no excess infection, though the trial was powered only for pain, so rare steroid or subscapularis-healing risks cannot be excluded.